Serotonin N-acetyltransferase: mechanism and inhibition.
Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) catalyzes the rate-limiting step in the biosynthesis of the circadian hormone melatonin from serotonin. Although melatonin was identified 40 years ago, relatively little is known about its (patho)physiological roles, and a solid scientific foundation is still lacking for most therapeutic applications currently claimed for melatonin. The development of potent, specific, and cell permeable inhibitors for AANAT should constitute an important strategy to address these issues. These inhibitors are also potential therapeutics for various sleep/mood disorders. This review will focus on the efforts toward developing in vitro and in vivo AANAT inhibitors, including basic mechanistic studies on AANAT, which have played an important role in design.
Zheng
Weiping
W
Department of Pharmacology and Molecular Sciences, the Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.
Cole
Philip A
PA
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D001191:Arylamine N-Acetyltransferase / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D001665:Binding Sites; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008550:Melatonin / Q000031:analogs & derivatives / Q000096:biosynthesis; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism
D004791:Enzyme Inhibitors; D010455:Peptides; D012701:Serotonin; D001191:Arylamine N-Acetyltransferase; D019883:Alkyl and Aryl Transferases; D008550:Melatonin